Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies [0.03%]
当前的复发性多发性硬化症疗法不会影响 Secondary Progressive Multiple Sclerosis 的发病状况
Francisco Coret,Francisco C Pérez-Miralles,Francisco Gascón et al.
Francisco Coret et al.
Background: Disease-modifying therapies are thought to reduce the conversion rate to secondary progressive multiple sclerosis. Objective: ...
High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis [0.03%]
中国多发性硬化患者队列中较高的 john cunder病毒抗体流行率和指数
Alexander Lau,Wei Qiu,Allan Kermode et al.
Alexander Lau et al.
We performed a cross-sectional study in 123 Chinese multiple sclerosis patients residing in Hong Kong to evaluate their anti-John Cunningham virus status using STRATIFY JCV DxSelect assays. Anti-John Cunningham virus antibody was present in...
MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response [0.03%]
MOG-IgG相关疾病具有典型的临床病程、无症状视力损害和良好的治疗应答
Lekha Pandit,Sharik Mustafa,Ichiro Nakashima et al.
Lekha Pandit et al.
Objectives: We investigated the clinical characteristics and treatment response in myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease and looked for evidence of subclinical disease. ...
DNA methylation changes in CD4+ T cells isolated from multiple sclerosis patients on dimethyl fumarate [0.03%]
二甲基富马酸治疗多发性硬化患者CD4⁺T细胞的表观遗传变化研究
Vicki E Maltby,Rodney A Lea,Karen A Ribbons et al.
Vicki E Maltby et al.
Background: Dimethyl fumarate is an oral treatment for multiple sclerosis, whose mechanism of action is not fully understood. Objective: ...
Patient perceived changes in sexual dysfunction after initiation of natalizumab for multiple sclerosis [0.03%]
natalizumab治疗多发性硬化症患者的性功能障碍变化感知评估
Derrick Robertson,Angela Aungst,Ryan Collier et al.
Derrick Robertson et al.
Purpose: Sexual dysfunction is a common but often overlooked secondary symptom of multiple sclerosis (MS) and can be associated with a decreased health-related quality of life (HRQoL). Natalizumab is a disease-modifying t...
Novel computer-based testing shows multi-domain cognitive dysfunction in patients with multiple sclerosis [0.03%]
新型计算机认知测试显示多发性硬化患者的多领域认知障碍
Andrew D Smith rd,Charles Duffy,Andrew D Goodman
Andrew D Smith rd
Background: Although cognitive dysfunction is a leading cause of disability and poor quality of life in patients with multiple sclerosis (MS), it is infrequently tested in routine clinical evaluation. Development of a cog...
Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials [0.03%]
青年多发性硬化症患者的复发率和磁共振成像活性：芬戈莫德三期临床试验的事后分析
Jutta Gärtner,Tanuja Chitnis,Angelo Ghezzi et al.
Jutta Gärtner et al.
Background: Disease activity differs in young patients with multiple sclerosis (MS) compared with the overall adult MS population. Objective: ...
Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric? [0.03%]
患者报告的疾病修正疗法在临床上的一致性：一种可靠的指标吗？
Devon S Conway,Maria Cecilia Vieira,Nicolas R Thompson et al.
Devon S Conway et al.
Background: Adherence to multiple sclerosis (MS) disease-modifying therapy (DMT) is commonly assessed through patient reporting, but patient-reported adherence is rarely studied. ...
Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study [0.03%]
一种混合方法心理测量研究：在复发缓解型多发性硬化症中解决ABILHAND-56的目标范围问题
Sophie Cleanthous,Sara Strzok,Farrah Pompilus et al.
Sophie Cleanthous et al.
Background: ABILHAND, a manual ability patient-reported outcome instrument originally developed for stroke patients, has been used in multiple sclerosis clinical trials; however, psychometric analyses indicated the measur...
Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study [0.03%]
TOWER研究中特立氟宁固定2年治疗期的临床疗效分析
Mark S Freedman,Julia Morawski,Karthinathan Thangavelu
Mark S Freedman
Patients enrolled in the phase 3 TOWER study (NCT00751881) of teriflunomide had variable treatment durations (48-173 weeks). This has led to challenges when interpreting results in the context of other phase 3 trials of disease-modifying th...